Search | Clinical Trials Finder

Conditions: Sedation
Interventions: Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Headache, Intranasal Ketamine
Interventions: Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Headache
Interventions: Compazine, Ketamine; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Complex Regional Pain Syndrome
Interventions: Ketamine, IV NSS, Normal Saline; Drug · Other
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Postoperative
Interventions: NMDA active, Steroid active, NMDA placebo, Steroid placebo; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Pain, Bunion, Abdominoplasty
Interventions: Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg; Drug
Lead sponsor: iX Biopharma Ltd.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Bronchoscopy
Interventions: Remifentanil, Fentanyl, Midazolam, Ketamine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Resistant Depressive Disorder
Interventions: Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more

Conditions: Abdominal Hysterectomy (& Wertheim)
Interventions: Lidocaine, Placebo, Ketamine, Ketamine + Lidocaine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Mayfield Heights, Ohio

Conditions: Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics
Interventions: Ketamine hydrochloride, Morphine sulphate; Drug
Lead sponsor: Columbia University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Los Angeles, California • Sacramento, California • Wilmington, Delaware + 5 more

Conditions: Opioid Use Disorder
Interventions: Treatment with Ketamine, Treatment with Very Low Dose Ketamine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bipolar Disorder
Interventions: Standard of Care, Ketamine, D-cycloserine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Headache
Interventions: Prochlorperazine, Ketamine, Diphenhydramine, Ondansetron, Normal Saline; Drug
Lead sponsor: University Medical Center of Southern Nevada; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Procedural Sedation
Interventions: midazolam / ketamine sublingual tablet; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anesthesia, Sedation and Analgesia, Interventional Radiology
Interventions: ketamine, Fentanyl (IV), Midazolam; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy
Interventions: General anesthetic, SA + ESP; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more

Conditions: Pain
Interventions: Placebo, ketamine 25 mg, ketamine 35 mg, ketamine 50 mg; Drug
Lead sponsor: Lotus Clinical Research, LLC; Other
Eligibility: 18 Years to 38 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Pasadena, California • Salt Lake City, Utah

Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Interventions: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block, 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block, Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed, 45-60 mg of 1.5% mepivacaine for spinal anesthesia, LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder
Interventions: Opioid-free anesthesia, Opioid-based anesthesia; Drug
Lead sponsor: Jacques E. Chelly; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more

Search by objective public record fields.

Alternative Sedation During Bronchoscopy

"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Lidocaine and Ketamine in Abdominal Surgery

Morphine or Ketamine for Analgesia

Ketamine for Opioid Use Disorder

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NMDA Antagonists in Bipolar Depression

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine

Prospective IR-led Sedation Feasibility

GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction

Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.

Transition From Acute to Chronic Opioid Use and Chronic Pain

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide